Topical Chemoprevention of Skin Cancer Biomarkers

Status Active, not recruiting

Clinical Trial Summary

This research study will test how well one topical medications work to prevent the development of non-melanoma skin cancers by reversing certain biomarkers in the skin. This study is also looking at the optimal dose of a medication in a small number of people. Biomarkers are molecules that are found in the body and inside of cells. Some biomarkers are associated with specific diseases such as skin cancer. In this study, one topical medication will be evaluated; diclofenac. Diclofenac and is approved by the Food and Drug Administration (FDA) for other uses. 24 patients will be enrolled in this study by University of Alabama at Birmingham.

Clinical Trial Description

Men and women (≥ 18 yo)who have been seen as patients in the Dermatology Clinic at the University of Alabama at Birmingham with a history of basal cell or squamous cell carcinoma of the skin and at least 8 actinic keratoses on the upper extremities are potentially eligible for study participation. We propose to examine one topical medication which is already FDA approved,with a placebo comparator. The purpose of the study is to see if diclofenac applied daily will affect levels of specific biomarkers in the skin that are associated with risk of developing skin cancer. We hope to see these levels decrease with once daily use of this medication. Results from this study will help guide us in a second study where we will look at longer term use of these medications and how they are associated with changes in skin biomarkers that are related to skin cancer. The second longer study will use the dose (once or twice daily topical application of diclofenac and DMFO) that resulted in a decrease in biomarkers, as discovered in this currently proposed study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02636569
Study type	Interventional
Source	University of Alabama at Birmingham
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 25, 2017
Completion date	December 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04103658` - NIR and Skin Cancer Margins	N/A
Completed	`NCT01053819` - Can We Miss Pigmented Lesions in Psoriasis Patients?	Phase 4
Recruiting	`NCT03767348` - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab	Phase 2
Recruiting	`NCT05429866` - Immunological Variables Associated to ICI Toxicity in Cancer Patients	Phase 2
Completed	`NCT02780934` - Comparing Pressure Versus Simple Adhesive Dressing After Mohs Reconstruction	N/A
Completed	`NCT02760160` - Dietary Prevention of Photodamage in Skin With Grapes	N/A
Completed	`NCT02872909` - Randomized Comparison of Low and Conventional Irradiance PDT for Skin Cancer	N/A
Withdrawn	`NCT03327064` - A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer	Phase 1/Phase 2
Completed	`NCT00342407` - The Incidence of Breast and Other Cancers Among Female Flight Attendants
Terminated	`NCT04410874` - Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer	Phase 1/Phase 2
Completed	`NCT03693937` - A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Completed	`NCT04334824` - Hydrochlorothiazide and Risk of Skin Cancer
Recruiting	`NCT05878288` - Deep sequencIng in Cutaneous Squamous CEll caRciNomas	Phase 2
Completed	`NCT01359735` - Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients	Phase 2
Terminated	`NCT04348916` - Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors	Phase 1
Enrolling by invitation	`NCT05257486` - Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
Withdrawn	`NCT03757663` - UV Dosimetry Feedback in NMSC Patients	N/A
Completed	`NCT04116983` - DERM NMSC Validation Study
Active, not recruiting	`NCT06227416` - Skin Tumor Biomarkers by Mass Spectrometry Imaging	N/A
Recruiting	`NCT05932511` - Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer	Early Phase 1